Long-Term Outcome with New Generation Prostheses in Patients Undergoing Transcatheter Aortic Valve Replacement
Open Access
- 14 July 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (14), 3102
- https://doi.org/10.3390/jcm10143102
Abstract
The aim of this study was to compare patients with transcatheter aortic valve replacement (TAVR) receiving new generation prostheses SAPIEN 3 (S3, Edwards Lifesc.) and Evolut R (ER, Medtronic Inc.) in terms of periprocedural and long-term outcome. Our retrospective, single-center analysis included 359 consecutive patients with severe aortic stenosis who underwent TAVR with S3 or ER from 2014–2016 (mean age 82 ± 7 years, 47% male, mean EuroSCORE II 8.0 ± 8%, mean follow-up 3.8 years). Device Success was equal (S3 93.0% vs. ER 92.4%, p = 0.812). We report a 30-day mortality of 2.8% in the S3 group, and 2.1% in the ER group (p = 0.674). There was no difference in stroke, conversion to open surgery, vascular and bleeding complications or myocardial infarction. While prosthesis mean gradients were higher with S3 (12.0 mmHg vs. 8.2 mmHg, p < 0.001), there was a trend to less paravalvular regurgitation (PVR moderate or severe: 1% vs. 3.6%, p = 0.088). All-cause mortality up to 5 years did not show a difference (mean survival S3 3.5 ± 0.24 years, ER 3.3 ± 0.29 years, p = 0.895). Independent predictors of long-term mortality were impaired LVEF, chronic kidney injury, peripheral artery disease, malignant tumor and periprocedural stroke. New generation TAVR valves offer an excellent implant and outcome success rate. Long-term survival was independent of prostheses choice and mainly attributed to comorbidities and complications.This publication has 24 references indexed in Scilit:
- Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk PatientsThe New England Journal of Medicine, 2016
- Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic ValveJournal of Invasive Cardiology, 2014
- 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive SummaryJournal of Invasive Cardiology, 2014
- Transcatheter Aortic Valve Replacement Using a Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at Extreme Risk for SurgeryJournal of Invasive Cardiology, 2014
- Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve ReplacementJAMA, 2014
- CT predictors of post-procedural aortic regurgitation in patients referred for transcatheter aortic valve implantation: an analysis of 105 patientsThe International Journal of Cardiovascular Imaging, 2013
- Updated Standardized Endpoint Definitions for Transcatheter Aortic Valve ImplantationJournal of Invasive Cardiology, 2012
- Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk PatientsThe New England Journal of Medicine, 2011
- Aortic regurgitation after transcatheter aortic valve implantation: incidence and early outcome. Results from the German transcatheter aortic valve interventions registryPublished by BMJ ,2011
- Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic StenosisJournal of the American College of Cardiology, 2002